Different nuclear binding sites for antiestrogen and estrogen receptor complexes. 1977

T S Ruh, and L J Baudendistel

Experiments were performed to determine the in vivo effect of various estrogens and anti-estrogens on the nuclear accumulation and retention of estrogen receptors, the cytoplasmic levels of estrogen receptors, and the formation of salt-resistant and salt-extractable forms of the nuclear estrogen receptor in immature rat uteri. A 5 mug injection of estradiol-17beta (E2) or diethylstilbestrol (DES) resulted in a maximal nuclear translocation of the receptor complexes by 1 h with a subsequent rapid decrease of both the estradiol receptor complex (ERC) and diethylstilbestrol receptor complex (DRC) to levels found in uteri of saline-injected rats by 12 h. However, the antiestrogens U-11,100A, zuclomiphene and enclomphene (100 mug/injection) resulted in a slower nuclear accumulation of receptor complex which continued to increase through 24 h. The cytosol receptor levels with E2 and DES were depleted to 10--20% of control levels within 1 h, but then were replenished so that they were above control levels by 24 h. The clomiphene-type compounds also showed an initial depletion of cytosol estrogen receptor, but the antiestrogens were almost ineffective in receptor replenishment. The estrogen receptor translocated to the nuclear fraction by estrogens demonstrated both salt-extractable (0.3M KCl) and salt-resistant forms at 1--6 h, whereas the clomiphene-type compounds resulted in the formation of only a salt-extractable form of the estrogen receptor at all times. By 12--24 h after injection, the salt-resistant forms of the ERC and DRC were no longer present. The effect of varying the dosage of injected E2 (0.05 mug-5 mug) resulted in the formation of an identical amount of salt-resistant ERC at 1--2 h, whereas the total amount of nuclear ERC (salt-resistant and salt-extractable) varied with the injected dose of E2. However, at 6 h, the amount of salt resistant ERC varied with the injected dose of E2 (0.005-5 mug). These results suggest that the nuclear salt-resistant form (formed by estrogens only) of the estrogen receptor is required for true uterine growth, whereas the nuclear salt-extractable form may be only sufficient for short term estrogenic responses.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009256 Nafoxidine An estrogen antagonist that has been used in the treatment of breast cancer. Nafoxidine Hydrochloride,U-11,100A,U-11000A,Hydrochloride, Nafoxidine,U 11,100A,U 11000A,U11,100A,U11000A
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D002996 Clomiphene A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue. Note that ENCLOMIPHENE and ZUCLOMIPHENE are the (E) and (Z) isomers of Clomiphene respectively. Chloramiphene,Clomifene,Clomid,Clomide,Clomifen,Clomiphene Citrate,Clomiphene Hydrochloride,Clostilbegit,Dyneric,Gravosan,Klostilbegit,Serophene,Citrate, Clomiphene,Hydrochloride, Clomiphene
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D004054 Diethylstilbestrol A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) Stilbestrol,Agostilben,Apstil,Diethylstilbestrol, (Z)-Isomer,Diethylstilbestrol, Disodium Salt,Distilbène,Stilbene Estrogen,Tampovagan,Estrogen, Stilbene
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004965 Estrogen Antagonists Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. Estradiol Antagonists,Antagonists, Estradiol,Antagonists, Estrogen
D005260 Female Females

Related Publications

T S Ruh, and L J Baudendistel
May 1986, European journal of cancer & clinical oncology,
T S Ruh, and L J Baudendistel
August 1973, The Journal of biological chemistry,
T S Ruh, and L J Baudendistel
December 1982, Endocrinology,
T S Ruh, and L J Baudendistel
August 1984, Biochemical and biophysical research communications,
T S Ruh, and L J Baudendistel
February 1983, Endocrinology,
T S Ruh, and L J Baudendistel
January 1996, Cancer treatment and research,
T S Ruh, and L J Baudendistel
January 1976, Journal of steroid biochemistry,
Copied contents to your clipboard!